Patrick Wood
Stock Analyst at Morgan Stanley
(3.36)
# 986
Out of 4,711 analysts
74
Total ratings
48%
Success rate
5.72%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Equal-Weight | $104 → $102 | $93.44 | +9.16% | 5 | Dec 6, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Overweight | $45 | $35.91 | +25.31% | 3 | Dec 2, 2024 | |
| GKOS Glaukos | Downgrades: Underweight | $120 | $150.88 | -20.47% | 3 | Dec 2, 2024 | |
| BLCO Bausch + Lomb | Downgrades: Equal-Weight | $19 | $18.00 | +5.56% | 6 | Dec 2, 2024 | |
| PRCT PROCEPT BioRobotics | Initiates: Overweight | $105 | $81.17 | +29.36% | 1 | Dec 2, 2024 | |
| SOLV Solventum | Maintains: Equal-Weight | $60 → $73 | $66.83 | +9.23% | 3 | Nov 11, 2024 | |
| PODD Insulet | Maintains: Overweight | $234 → $317 | $266.57 | +18.92% | 5 | Nov 11, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $92 → $100 | $88.95 | +12.42% | 4 | Oct 24, 2024 | |
| EW Edwards Lifesciences | Reinstates: Equal-Weight | $70 | $74.81 | -6.43% | 7 | Oct 11, 2024 | |
| DXCM DexCom | Maintains: Equal-Weight | $120 → $75 | $80.04 | -6.30% | 6 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $12.00 | -16.67% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $104 → $145 | $61.70 | +135.01% | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $65 → $85 | $84.76 | +0.28% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $24.82 | +49.07% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $39 → $30 | $29.50 | +1.69% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $86 | $78.91 | +8.98% | 5 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $225 → $215 | $207.49 | +3.62% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $310 → $280 | $227.68 | +22.98% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $178.16 | - | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $33.66 | +6.95% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $151.85 | - | 5 | Dec 11, 2017 |
The Cooper Companies
Dec 6, 2024
Maintains: Equal-Weight
Price Target: $104 → $102
Current: $93.44
Upside: +9.16%
Tandem Diabetes Care
Dec 2, 2024
Upgrades: Overweight
Price Target: $45
Current: $35.91
Upside: +25.31%
Glaukos
Dec 2, 2024
Downgrades: Underweight
Price Target: $120
Current: $150.88
Upside: -20.47%
Bausch + Lomb
Dec 2, 2024
Downgrades: Equal-Weight
Price Target: $19
Current: $18.00
Upside: +5.56%
PROCEPT BioRobotics
Dec 2, 2024
Initiates: Overweight
Price Target: $105
Current: $81.17
Upside: +29.36%
Solventum
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $60 → $73
Current: $66.83
Upside: +9.23%
Insulet
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $266.57
Upside: +18.92%
Boston Scientific
Oct 24, 2024
Maintains: Overweight
Price Target: $92 → $100
Current: $88.95
Upside: +12.42%
Edwards Lifesciences
Oct 11, 2024
Reinstates: Equal-Weight
Price Target: $70
Current: $74.81
Upside: -6.43%
DexCom
Jul 26, 2024
Maintains: Equal-Weight
Price Target: $120 → $75
Current: $80.04
Upside: -6.30%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $12.00
Upside: -16.67%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $61.70
Upside: +135.01%
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $84.76
Upside: +0.28%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $24.82
Upside: +49.07%
Jul 15, 2024
Downgrades: Underweight
Price Target: $39 → $30
Current: $29.50
Upside: +1.69%
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $74 → $86
Current: $78.91
Upside: +8.98%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $207.49
Upside: +3.62%
Dec 4, 2023
Maintains: Overweight
Price Target: $310 → $280
Current: $227.68
Upside: +22.98%
Dec 4, 2023
Upgrades: Overweight
Price Target: n/a
Current: $178.16
Upside: -
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $33.66
Upside: +6.95%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $151.85
Upside: -